A b s t r a c t
B-5 has long been used in the fixation of hematopoietic tissues owing to the superior morphologic detail achieved. However, there are drawbacks to the use of B-5, which have become more of an issue during the last 5 to 10 years. B-5 has strict fixation times that can disrupt workflow and easily result in overfixed, brittle tissue. Difficulty in handling B-5-fixed tissues requires processing by experienced histology technicians who are in short supply nationally. Antigen retrieval is difficult for a number of key antibodies, in particular CD30 and cyclin D1. The inability to perform molecular studies is more and more of a problem because they are becoming a standard diagnostic tool in many settings. Finally, safety and disposal requirements in the laboratory are problematic.
Because B-5 fixative contains mercuric chloride (HgCl 2 ), its use raises safety concerns. Numerous acute and chronic toxic effects have been described in association with mercury exposure. Exposure in humans can affect the central and peripheral nervous systems, lungs, kidneys, skin, and eyes. 1, 2 These safety concerns and reported toxic effects have led to increasingly strict regulations from several agencies, including the US Food and Drug Administration, the Occupational Safety and Health Administration, and state regulatory agencies, regarding the handling of mercury-containing compounds.
In addition to the safety of laboratory personnel, there are issues regarding community safety from disposal of mercurycontaining compounds. James Harvie, 3 a pollution-prevention specialist, identified numerous sources of mercury contamination, including solid waste and waste-water, related to the use of B-5 in hospital laboratories. Subsequently, the study hospitals successfully converted to mercury-free fixatives, despite concerns about suboptimal fixation and tissue morphologic detail. 3 Owing to the increasing awareness of the extent of environmental pollution, the Environmental Protection Agency and interstate regulatory agencies likewise have increased regulations regarding transport, handling, and disposal of mercury-containing compounds. 4 In 1998, a voluntary agreement was reached between the Environmental Protection Agency and the American Hospital Association to reduce environmental waste. 5 Other organizations and hospitals are following suit. For example, the National Institutes of Health has initiated a mercury-free campaign. 6 For the multitude of aforementioned reasons, our own laboratory designed a blinded, prospective study to find a safer, mercury-free, alternative fixative with morphologic detail comparable to B-5 fixation.
Materials and Methods
Step 1: H&E Staining, Decalcification, Handling, and Processing Six fixatives, including B-5, were incorporated into a blinded review by 4 pathologists (including K.F. and C.E.S.): acetic acid-zinc-formalin (AZF) and modified B-5-1 (Newcomer Supply, Middleton WI), modified B-5-2 (Master*Tech Scientific, Lodi, CA), Fix-All (Surgipath, Richmond, IL), and B-Plus Fixative (Mercedes Medical, Sarasota, FL). AZF, modified B-5-1, and modified B-5-2 contain various concentrations of formaldehyde, zinc chloride, and acetic acid. AZF is a working solution, whereas the modified B-5 solutions are zinc chloride stock solutions requiring the addition of formaldehyde with or without acetic acid. FixAll is an alcohol-based fixative, and B-Plus Fixative contains 3.7% formaldehyde, less than 1% zinc chloride, and selected buffers. H&E staining was performed according to established staining protocols on an automated system.
Comparison of H&E morphologic features and staining quality on 4 sets of slides with the various fixatives was performed. All 4 sets used tonsil tissue owing to its easy availability and hematopoietic nature. In the first 3 sets, all fixatives were used. In addition, set 3 included intentionally large tissue fragments to evaluate the fixatives' ability to penetrate and achieve adequate fixation. Each set was scored by 3 or 4 pathologists in a blinded manner for evaluation of overall morphologic detail and staining quality on the H&E-stained slides, graded on a scale of 1-4 (1, good; 2, satisfactory; 3, suboptimal; 4, poor). After the first 3 sets were evaluated, 2 of the alternative fixatives were dropped from the study owing to consistently poor results reported by all pathologists.
Optimal morphologic detail and H&E staining also were evaluated on decalcified tissue samples (bone marrow core biopsy specimens) for the selected alternative fixative (AZF) using 2 rapid decalcifiers, RDO (IMEB, San Marcos, CA) and Decal Stat (Decal, Tallman, NY). Standard decalcification led to an unusual retraction artifact in the decalcified bone marrow specimens. Therefore, further evaluation on decalcified tissue specimens was performed, including modification of decalcification times and rinsing. Ultimately, the decalcification step was followed by a 5-minute water rinse with near resolution of the artifact.
Finally, during this phase of the study, the technical issues regarding handling, disposal, and processing, including cutting sections and staining, were evaluated for each of the 6 fixatives by a histotechnologist (P.B.).
Step 2: Immunohistochemical Analysis and In Situ Hybridization
Initial immunohistochemical evaluation was performed on AZF-fixed tonsil tissue samples. CD3, CD20, and Ki-67 were chosen for initial evaluation because they are used routinely in the assessment of hematopoietic cases and because they provide a combination of cellular localization patterns, including cytoplasmic, membranous, and nuclear.
Additional antibodies, including CD4, CD8, CD10, CD30, CD34, CD68, bcl-2, cyclin D1, terminal deoxynucleotidyl transferase, T-cell intracytoplasmic antigen-1, and κ and λ light chains, were evaluated on an individual basis as relevant case material became available during a 6-month period ❚Table 1❚. Initially, immunohistochemical staining procedures were not altered from previous protocols. Tissue sections were cut at 5 µm, deparaffinized, rehydrated, and treated with 3% hydrogen peroxide for 4 minutes. Antigen retrieval, automated antibody application, and staining based on an avidin-biotin system were performed using the same protocols established for formalin-fixed tissue samples. The κ and λ light chains also were evaluated by in situ hybridization according to manufacturer protocols (Ventana, Tucson, AZ).
Step 3: DNA Extraction and Amplification By using established procedures for molecular studies on paraffin-embedded, formalin-fixed tissue samples, DNA extraction and polymerase chain reaction (PCR)-based amplification of β-actin was performed on paraffin-embedded, AZF-fixed tissue samples.
Results
Step 1: H&E Staining, Decalcification, Handling, and Processing Scores within individual sets and the overall average score were best for B-5-fixed sections (overall staining average, 1.5; overall morphologic average, 1.3). However, AZFfixed sections consistently scored a close second (overall staining average, 1.8; overall morphologic score, 1.5). B-Plus Fixative also was a viable alternative and consistently scored third (overall staining average, 2.1; overall morphologic average, 2.1). Fix-All was not considered a viable alternative based on scoring results (overall staining average, 2.4; overall morphologic average, 2.5) because AZF and B-Plus Fixative consistently scored higher. Finally, both modified B-5 solutions consistently received inferior scores and were eliminated from further study ❚Table 2❚ and ❚Image 1❚.
In the final set for H&E evaluation, only B-5, AZF, BPlus Fixative, and Fix-All were included, and scores consistent with those in the first 3 sets were obtained.
AZF fixation in conjunction with 2 rapid decalcification solutions was evaluated. RDO had a significantly longer processing time. At 30 minutes, bone marrow core biopsy specimens still were mineralized and could not be cut. Although decalcification could be achieved between 10 and 15 minutes with Decal Stat, the best results were obtained at 30 minutes. As discussed in the "Materials and Methods" section, a 5-minute water rinse was incorporated after the decalcification step and led to near resolution of a retraction artifact in the bone marrow biopsy specimens. This artifact is not observed on clot sections. Morphologic detail and staining in decalcified bone marrow specimens were comparable for AZF and B-5 ❚Image 2❚.
Handling and processing requirements were evaluated during this phase by a histotechnologist (P.B.) who found superior handling and disposal for all of the non-mercurybased fixatives. In particular, AZF requires only a simple chemical neutralization step with anhydrous sodium carbonate followed by sink disposal. Also, AZF was found to have greater ease of tissue sectioning and superior fixation times, leading to more efficient workflow and turnaround time. While a minimum of 2 hours of fixation in AZF is required to obtain the morphologic benefits, fixation times up to 72 hours did not adversely affect sectioning or morphologic quality. Tissue samples transported in buffered formalin can be postfixed in AZF (2 hours) to improve morphologic detail. Overall characteristics of B-5 and AZF are given in ❚Table 3❚. The combined data from phase 1 of the study led to the selection of AZF as an alternative fixative for additional studies, with immunohistochemical analysis, in situ hybridization, and DNA extraction and amplification.
Step 2: Immunohistochemical Analysis and In Situ Hybridization
Initial evaluation of CD3, CD20, and Ki-67 demonstrated excellent staining in AZF-fixed tonsil tissue samples. This combination of stains demonstrated the ability to achieve high-quality staining in AZF-fixed tissue for all subcellular locations, including nuclear (Ki-67), cytoplasmic (CD3), and membranous (CD20).
Subsequent cases of diffuse large B-cell lymphoma, follicular lymphoma, CD30+ cutaneous lymphoma, and peripheral T-cell lymphoma and a bone marrow specimen with increased blasts provided the opportunity to evaluate additional stains commonly used in the diagnosis of hematopoietic neoplasms. In all cases, the staining quality was comparable or superior to that seen in B-5-and formalin-fixed tissue samples. The staining quality in most of these cases was based on the subjective experience of the involved pathologists. However, 1 known case of CD30+ cutaneous lymphoma had a repeated biopsy, allowing portions of tissue from the same case to be fixed in formalin, B-5, or AZF. Tissue samples from the alternative fixatives were processed in parallel and embedded in the same paraffin tissue block for side-by-side staining comparison with CD4, Ki-67, and CD30 ❚Image 3❚.
In situ hybridization consistently demonstrated strong signals for κ and λ light chains in plasma cells during the study period. During subsequent use, we also have observed weaker but diagnostic signals in other lymphoproliferative disorders such as immunoblastic lymphomas and some mucosa-associated lymphoid tissue lymphomas.
Step 3: DNA Extraction and Amplification
Extraction and amplification of DNA for the β-actin gene was achieved in test cases fixed with AZF. AZF, acetic acid-zinc-formalin. * AZF requires room temperature storage in a dry, well-ventilated area away from heat, flame, and spark and separate from oxidizing agents and alkalies.
Discussion
Overall, AZF was found to be a viable alternative to B-5 fixation. B-Plus Fixative was a close second as an alternative to B-5. Modified B-5 options were suboptimal and dropped from the study evaluation early owing to consistently inferior results in H&E staining quality and overall morphologic detail.
In the blinded slide reviews, AZF was considered a close second to B-5 in regard to H&E staining quality and the morphologic detail achieved. In fact, as processing times and the staining protocol were refined, the gap between the two was narrowed further, and many of the reviewers no longer noted any significant difference between the 2 fixatives. Therefore, AZF was chosen as the new fixative for hematopoietic specimens because it achieved both objectives of the project.
First, AZF is mercury-free, which improves safety. The absence of mercury eliminates the difficulties and cost associated with mercury-containing B-5 regarding handling and disposal. Second, the staining quality and morphologic detail yields diagnostic accuracy comparable to that of B-5.
In addition to the primary objectives, several additional advantages to the use of AZF were noted during the study. Because there is no mercury in the AZF fixative, the tissue sections can go directly into the staining solutions without a washing step. With B-5, a washing step (iodine, 5 minutes; hypotonic rinse, 5 minutes) had to be performed in the middle of the H&E staining sequence. This untimely wash step necessitated hand staining of B-5-fixed specimens. AZF does not require this step, thus saving time directly through elimination of the wash step. In addition, elimination of the B-5 wash steps allowed incorporation of AZF-fixed hematologic specimens on the automated stainer without the requirement for labor-intensive hand staining. Because of its low toxicity, small quantities of AZF can be discarded in the sink. Even large-quantity disposal is straightforward, requiring only a chemical neutralization step.
In addition, because AZF is ready-made and does not require a mixing step as does B-5, it can be used in clinics and office-based sites with ease. There also is greater flexibility in the time a specimen is in AZF compared with B-5. Specimens can be placed directly into this fixative and transported to the histology laboratory. This saves on fixative transfer steps and allows the specimen to begin fixation in the appropriate solution immediately after it is obtained.
On the other hand, there is no maximum amount of time that a specimen can be in AZF; we confirmed that there were no adverse effects on staining quality or immunoperoxidase sensitivity up to 72 hours, the maximum time tissue specimens would be in fixative over a weekend. In comparison, B-5 overfixation can lead to extremely brittle tissue that cracks, is difficult to cut, and might not adhere to the slide. The ease of cutting AZF vs B-5-fixed tissue samples is another advantage that was noted by the histotechnologist in our laboratory during the study. This leads to less labor time dealing with difficult tissue samples and improved sections leading to better staining and morphology.
Processing and turnaround times also are improved by the presence of acetic acid in the AZF fixative, which "prestarts" the decalcification step for bone marrow specimens. Decalcification has been achieved in as little as 15 minutes. However, optimal decalcification occurs at 30 minutes following 2 hours in AZF. This is shortened from the 2-hour decalcification time required following B-5 fixation. This means that many late afternoon specimens can be processed the same day.
AZF provides greater flexibility for workflow, eliminates labor-intensive steps, saves processing time, and improves turnaround time.
As a quality control measure, an initial round of immunohistochemical studies with CD3, CD20, and Ki-67 was performed to document satisfactory staining in AZF-fixed tissue samples for all subcellular locations. Adequate staining in AZF-fixed tissue also was demonstrated with side-by-side staining performed on formalin-, B-5-, and AZF-fixed tissue samples from a single case. Finally, subjective evaluation was performed on numerous additional cases with a variety of antibodies by the primary pathologist involved in the study (C.E.S.). This evaluation included antibodies frequently used in bone marrow specimens, such as myeloperoxidase, lysozyme, CD31, CD117, and hemoglobin A. No interpretive difficulties were encountered owing to AZF fixation during this 6-month evaluation period. The only remaining challenges are some nuclear antibodies such as cyclin D1 and Ki-67, which stain readily in nondecalcified, AZF-fixed tissue specimens such as lymph nodes and clot sections but often show inconsistent or no staining on decalcified bone marrow biopsy specimens. This problem also is seen in standard formalin fixation.
Our experience with PCR-based molecular analysis of AZF-fixed tissue is limited because fresh tissue samples are obtained routinely on bone marrow and lymph node specimens, providing the most optimal material for molecular and flow cytometric studies. Nevertheless, we documented amplification of β-actin by PCR without difficulty. These results are similar to the previously reported feasibility of recovery of genomic DNA from zinc-based fixatives. 7 At the time of this report, AZF had been used successfully for routine processing of bone marrow and lymphoid tissue specimens as established in our laboratory for almost 3 years with diagnostic accuracy similar to that with B-5 fixation. However, because H&E staining, immunohistochemical analysis, and in situ hybridization are complex, multistep procedures, the findings of this study do not preclude successful use of other mercury-free fixatives in other laboratories with different protocols.
